120 related articles for article (PubMed ID: 37097665)
21. Anti-Cancer Effects of CDK4/6 Inhibitor LEE011 and Chemotherapy Drugs on Lymphocytic Leukemia L1210 Cells.
Lin YC; Lin YH; Chang YU; Su YC; Hsieh WC; Chen WH; Lee HM
Anticancer Res; 2024 Mar; 44(3):1121-1130. PubMed ID: 38423629
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment.
Zhang R; Luo Y; Du C; Wu L; Wang Y; Chen Y; Li S; Jiang X; Xie Y
Bioorg Med Chem Lett; 2023 Feb; 81():129128. PubMed ID: 36639036
[TBL] [Abstract][Full Text] [Related]
23. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
[TBL] [Abstract][Full Text] [Related]
24. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
25. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
Zhao D; Wu D; Zhang G; Li Y; Shi W; Zhong B; Yu H
Mol Biol Rep; 2022 Sep; 49(9):8359-8368. PubMed ID: 35764749
[TBL] [Abstract][Full Text] [Related]
26. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T; Takimoto R; Ono M; Hirakawa M; Yoshida M; Okagawa Y; Uemura N; Arihara Y; Sato Y; Tamura F; Sato T; Iyama S; Miyanishi K; Takada K; Hayashi T; Kobune M; Kato J
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628655
[TBL] [Abstract][Full Text] [Related]
27. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma.
Amin N; Wang H; Song Q; Bhaskar M; Yadav SP; Gilbert MR; Pant H; Tabouret E; Zhuang Z
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511490
[TBL] [Abstract][Full Text] [Related]
28. A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle.
Li Y; Zhao D; Zhang W; Yang M; Wu Z; Shi W; Lan S; Guo Z; Yu H; Wu D
J Transl Med; 2023 Jun; 21(1):422. PubMed ID: 37386467
[TBL] [Abstract][Full Text] [Related]
29. Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer.
Yoon S; Lee BK; Kim KP
Phytomedicine; 2023 Dec; 121():155120. PubMed ID: 37806154
[TBL] [Abstract][Full Text] [Related]
30. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
31.
Long ZH; Bai ZG; Song JN; Zheng Z; Li J; Zhang J; Cai J; Yao HW; Wang J; Yang YC; Yin J; Zhang ZT
Anticancer Res; 2017 Aug; 37(8):4345-4352. PubMed ID: 28739727
[TBL] [Abstract][Full Text] [Related]
32. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.
Lopes F; Smith R; Nash S; Mitchell RT; Spears N
Mol Hum Reprod; 2016 Nov; 22(11):745-755. PubMed ID: 27470502
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Plasencia C; Abad A; Martinez-Balibrea E; Taron M
Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
[TBL] [Abstract][Full Text] [Related]
35. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
36. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L
Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Evaluation of Glucose Transporter Inhibitor-SN38 Conjugates for Targeting Colorectal Cancer.
Chiu PF; Chang CK; Huang PS; Lin YY; Lin CS; Yang HY; Hsu LC; Yu LC; Liang PH
J Med Chem; 2023 Jul; 66(14):9684-9696. PubMed ID: 37413981
[TBL] [Abstract][Full Text] [Related]
39. Preclinical antitumor activity of a nanoparticulate SN38.
Al-Kasspooles MF; Williamson SK; Henry D; Howell J; Niu F; Decedue CJ; Roby KF
Invest New Drugs; 2013 Aug; 31(4):871-80. PubMed ID: 23299391
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.
Cao Y; Jin ZX; Tong XP; Yue S; Sakai T; Kawanami T; Sawaki T; Miki M; Iwao H; Nakajima A; Masaki Y; Fukushima Y; Fujita Y; Nakajima H; Okazaki T; Umehara H
Anticancer Res; 2010 Oct; 30(10):3911-7. PubMed ID: 21036702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
